<DOC>
	<DOCNO>NCT01376713</DOCNO>
	<brief_summary>The purpose study ass overall disease control rate Ofatumumab wo/w Dacarbazine subject American Joint Committee Cancer ( AJCC 2009 ) unresectable stage III stage IV melanoma .</brief_summary>
	<brief_title>Anti-CD20 ( Cluster Differentiation Antigen 20 ) Therapy Treat Metastatic Melanoma</brief_title>
	<detailed_description>This prospective , multicenter , open-label , sequential , 2-cohort , phase 2 study ass overall disease control rate Ofatumumab accord criterion RECIST ( Response Evaluation Criteria Solid Tumors ) v. 1.1. subject unresectable stage III B ( T1- 4a , N2b-c ) , stage III C stage IV ( American Joint Committee Cancer 2009 ) disease . Cohort 1 : 10 eligible patient treat ofatumumab alone . If interim analysis show least 1 confirm overall response occur , additional 19 eligible patient treat , total 29 patient . Cohort 2 : If confirm overall response ofatumumab alone-therapy see first 10 patient , cohort 2 open . Initially , 13 eligible patient treat combination Dacarbazine plus ofatumumab . If interim analysis give least 2 confirm overall response , additional 26 patient recruit .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients older 18 year Signed informed consent Metastatic nonocular melanoma unresectable stage III B ( T1 4a , N2bc ) , stage III C ( AJCC 2009 ) stage IV ( AJCC 2009 ) . measurable disease one metastatic lesion , accord RECIST v. 1.1 criterion , One metastases must resectable prior antiCD20 therapy . ECOG ( Eastern Cooperative Oncology Group ) performance status 02 . As soon BRAF kinase inhibitor standard care , include patient consider therapy . E.g . patient tumor carry respective mutational profile , patient refuse kind therapy reason , patient eligible therapy due contraindication disease progression kind therapy . Life expectancy 3 month longer Negative pregnancy test female patient childbearing potential adequate contraception female patient childbearing age . Patients active brain metastasis ( exception : brain metastasis stable without corticosteroid 2 month treatment surgery radiation therapy ) immunoglobulindeficiency exclude . Subjects meet follow criterion must enrol ofatumumab study : Subjects current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) Treatment know nonmarketed drug substance experimental therapy within 5 terminal half live 4 week prior enrollment , whichever longer , currently participate interventional clinical study Other past current malignancy . Subjects free malignancy least 5 year , history completely resect nonmelanoma skin cancer , successfully treat situ carcinoma eligible . Chronic current infectious disease require systemic antibiotic , antifungal , antiviral treatment , limited , chronic renal infection , chronic chest infection bronchiectasis , tuberculosis active Hepatitis C. History significant cerebrovascular disease past 6 month ongoing event active symptom sequelae HIV positive Clinically significant cardiac disease include unstable angina , acute myocardial infarction within six month prior enrollment , congestive heart failure ( NYHA IIIIV ) , arrhythmia unless controlled therapy , exception extra systole minor conduction abnormality . Positive serology Hepatitis B ( HB ) define positive test HBsAg . In addition , negative HBsAg HBcAb positive ( regardless HBsAb status ) , HB DNA test perform positive subject exclude . Positive serology hepatitis C ( HC ) define positive test HCAb ( HC antibody ) , case reflexively perform HC RIBA ( recombinant immunoblot assay ) sample confirm result Screening laboratory value : hemoglobin &lt; 8g/dL platelet &lt; 70 x 109/L leukocyte &lt; 1.5 x 109/L creatinine &gt; 2.0 time ULN ( upper limit normal ) total bilirubin &gt; 1.5 time ULN liver transaminase ALT &gt; 2.5 time ULN alkaline phosphatase &gt; 2.5 time ULN Pregnant lactate woman Male subject unable unwilling use adequate contraception method study start one year last dose protocol therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Melanoma</keyword>
</DOC>